A retrospective study to investigate safety and the efficacy of Nivolumab in patients with relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation.

Trial Profile

A retrospective study to investigate safety and the efficacy of Nivolumab in patients with relapsed or refractory Hodgkin's lymphoma after allogeneic hematopoietic cell transplantation.

Completed
Phase of Trial: Phase IV

Latest Information Update: 16 Mar 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications Hodgkin's disease
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 16 Mar 2017 New trial record
    • 07 Mar 2017 Results published in the Blood
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top